Please summarize guidance and clinical trials surrounding when to get an EKG when using dofetilide therapy.

Comment by InpharmD Researcher

Dofetilide prescribing information and professional guidance recommend baseline QTc/QT assessment before the first dose, initiation or re-initiation with continuous ECG monitoring for at least 3 days, and QTc/QT reassessment 2 to 3 hours after each inpatient dose through doses 2 to 5. The 2023 ACC/AHA/ACCP/HRS atrial fibrillation guideline similarly recommends inpatient monitoring with baseline ECG, continuous ECG monitoring, renal function assessment, and electrolyte monitoring, followed by repeat ECG and laboratory monitoring every 3 to 6 months. Clinical trials, including SAFIRE-D and DIAMOND, used inpatient telemetry/continuous monitoring with renal-based dosing and QT/QTc-based dose adjustment or discontinuation, with torsades events reported during early initiation. Overall, ECG monitoring is recommended before initiation, throughout inpatient loading or reloading, after dose changes, and during maintenance therapy.

Background

The 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation states that dofetilide initiation or reloading is generally performed with admission for at least 3 days to a health care facility capable of creatinine clearance calculation, continuous electrocardiographic monitoring, and cardiac resuscitation; recommended monitoring includes a baseline 12-lead electrocardiograph (ECG) to assess rhythm and calculate QTc, continuous ECG monitoring during the 3-day hospitalization for initiation, and serum potassium, magnesium, and creatinine assessment for CrCl estimation. After discharge on a stable dose, the guideline recommends repeat 12-lead ECG, serum potassium and magnesium concentrations, and serum creatinine for CrCl estimation at 3 to 6 months and every 3 to 6 months thereafter, with more frequent monitoring for patients receiving concomitant QT interval-prolonging drugs or with changing kidney function. The guideline’s supporting evidence notes that dofetilide is associated with torsades de pointes, with reported incidence ranging from 0.9% to 3.3% and potentially higher when dosing is not adjusted for kidney function; in SAFIRE-D, patients underwent a minimum 3-day hospitalization, and among 241 patients randomized to dofetilide, 10 had QTc prolongation within the first 3 days and 2 had torsades de pointes degenerating to ventricular fibrillation. Additional cited evidence includes an AFFIRM substudy in which 1 of 12 dofetilide-treated patients experienced torsades de pointes, a retrospective cohort of 378 patients showing torsades de pointes rates of 1.3% with dofetilide versus 1.2% with sotalol during inpatient initiation, a systematic review reporting 1% to 10% torsades de pointes incidence with the highest risk in HFrEF and higher-than-recommended or non-renally adjusted doses, and 2 DIAMOND randomized trials in which all patients were hospitalized for at least 3 days after initiation and torsades de pointes occurred in 25 of 762 patients and 7 of 749 patients, with most events occurring within the first 3 days of dosing. [1]

A 2017 American Heart Association scientific statement on electrocardiographic monitoring in hospitalized patients states that dofetilide is an antiarrhythmic drug with known risk for torsade de pointes, and recommends QTc monitoring for patients started on dofetilide as a Class I recommendation with Level of Evidence B; the same table specifies that U.S. Food and Drug Administration guidance applies, and that for patients with a Class I indication for QT monitoring, the QTc, including a rhythm strip, should be documented at baseline and at least every 8 to 12 hours, with QTc documentation before and after dose increases of QT-prolonging drugs. The statement further notes that if QTc prolongation occurs during drug administration, more frequent measurement may be needed, and that if QTc exceeds 500 ms, the causative drug should be discontinued and QTc monitoring continued until drug washout and a decreasing QTc are documented. In the atrial tachyarrhythmia section, the statement reports that a 2006 meta-analysis of 44 trials including more than 11,000 patients found that Class IC agents and Class III agents, including dofetilide, reduced recurrent atrial tachyarrhythmias after cardioversion of atrial fibrillation; however, it also states that antiarrhythmics other than amiodarone and propafenone increased proarrhythmias, with risk most commonly occurring during initiation, and that inpatient ECG monitoring is required by the FDA for 3 days during dofetilide initiation because of the risk of QT prolongation and ventricular arrhythmias. [2]

Relevant Prescribing Information

BOXED WARNING [3]
To minimize the risk of induced arrhythmia, patients initiated or re-initiated on dofetilide should be placed for a minimum of 3 days in a facility that can provide calculations of creatinine clearance, continuous electrocardiographic monitoring, and cardiac resuscitation.

CLINICAL STUDIES [3]
In the DIAMOND studies, all patients were hospitalized for at least 3 days after treatment was initiated and monitored by telemetry.

DOSAGE AND ADMINISTRATION [3]
Initiation of dofetilide Therapy
Step 1. Electrocardiographic assessment: Prior to administration of the first dose, the QTc or QT must be checked using an average of 5 to10 beats. If the QTc or QT is greater than 440 msec (500 msec in patients with ventricular conduction abnormalities), dofetilide is contraindicated. If heart rate is less than 60 beats per minute, QT interval should be used. Proceed to Step 2 if the QTc or QT is 440 msec. Patients with heart rates <50 beats per minute have not been studied.
Step 5. At 2 to 3 hours after administering the first dose of dofetilide, determine the QTc or QT (if heart rate is less than 60 beats per minute).
Step 6. At 2 to 3 hours after each subsequent dose of dofetilide, determine the QTc or QT (if heart rate is less than 60 beats per minute) (for in-hospital doses 2 to 5).
Maintenance of Dofetilide Therapy
Renal function and QTc or QT (if heart rate is less than 60 beats per minute) should be re-evaluated every three months or as medically warranted. If QTc or QT exceeds 500 milliseconds (550 msec in patients with ventricular conduction abnormalities), dofetilide therapy should be discontinued and patients should be carefully monitored until QTc or QT returns to baseline levels.

Literature Review

A search of the published medical literature revealed 3 studies investigating the researchable question:

Please summarize guidance and clinical trials surrounding when to get an EKG when using dofetilide therapy.

Level of evidence

C - Multiple studies with limitations or conflicting results Read more→

Please see Tables 1-3 for your response.

Efficacy and Safety of Oral Dofetilide in Converting to and Maintaining Sinus Rhythm in Patients With Chronic Atrial Fibrillation or Atrial Flutter
Design	Double-blind, multicenter, placebo-controlled study N= 325
Objective	To determine the efficacy and safety of dofetilide in converting atrial fibrillation (AF) or atrial flutter (AFl) to sinus rhythm (SR) and maintaining SR for 1 year
Study Groups	125 mg dofetilide (n= 82) 250 mg dofetilide (n= 82) 500 mg dofetilide (n= 77) Placebo (n= 84)
Inclusion Criteria	Patients aged 18 to 85 years with AF/AFl for 2 to 26 weeks, confirmed by electrocardiograph (ECG)
Exclusion Criteria	Women of childbearing potential, inability to tolerate withdrawal from current antiarrhythmic therapy, syncope of unknown origin in the preceding 6 months, active thyrotoxicosis, AF or AFl from reversible noncardiac diseases, uncompensated or rapidly progressive congestive heart failure, recent myocardial infarction or unstable angina, significant sinus node abnormalities, major hematological, pulmonary, hepatic, or renal disease, and history of substance dependency or abuse
Methods	Patients were randomized to 125, 250, or 500 mg dofetilide or placebo twice daily. Dosages were adjusted for QTc response and creatinine clearance. Patients were monitored for conversion to SR and maintenance of SR over 1 year. Safety was evaluated through physical examination, ECG analysis, and recording of adverse events.
Duration	3 days or 5 doses for conversion phase, followed by a 12-month maintenance phase
Outcome Measures	Conversion to sinus rhythm (SR) and maintenance of SR for 1 year; time to first relapse to AF/AFl, incidence of proarrhythmic events
Baseline Characteristics		125 mg BID (n= 82)	250 mg BID (n= 82)	500 mg BID (n= 77)	Placebo (n= 84)
	Female	14	13	14	11
	Mean age, years (range)	66 (30–88)	68 (39–86)	67 (33–87)	67 (37–85)
	Primary diagnosis AF AFl	70 (85%) 12 (15%)	75 (91%) 7 (9%)	65 (84%) 12 (16%)	67 (80%) 17 (20%)
	NYHA class I II III	22 (28%) 51 (64%) 7 (9%)	24 (29%) 48 (59%) 10 (12%)	21 (27%) 52 (68%) 4 (5%)	22 (26%) 58 (69%) 4 (5%)
Results		125 mg BID (n= 82)	250 mg BID (n= 82)	500 mg BID (n= 77)	Placebo (n= 84)
	Pharmacological conversion rate	6.1%	9.8%	29.9%	1.2%
	Probability of maintaining SR at 1 year	0.40	0.37	0.58	0.25
	Median time to relapse, days	31	179	>365	27
Adverse Events	Two cases of torsade de pointes (0.8% of all patients given active drug); one sudden cardiac death classified as proarrhythmic (0.4% of all patients given active drug).
Study Author Conclusions	Dofetilide, a new class III antiarrhythmic agent, is moderately effective in cardioverting AF or AFl to SR and significantly effective in maintaining SR for 1 year once patients are pharmacologically or electrically converted. In-hospital initiation and dosage adjustment based on QTc and Cl_Cr are necessary to minimize a small but nonnegligible risk of proarrhythmic or sudden death. Withdrawal from treatment during maintenance of SR is low. Dofetilide should be considered an important new treatment option for patients with AF or AFl.
Critique	SAFIRE-D is highly relevant to EKG monitoring during dofetilide initiation because its protocol operationalized risk mitigation through inpatient telemetry, creatinine-clearance-based dosing, and QT/QTc-triggered dose reduction or withdrawal. The key clinical takeaway is that the most consequential proarrhythmic events occurred early, torsade on days 2 and 3 and sudden death on day 8, supporting intensive ECG monitoring during initiation and after early dosing changes; however, the study provides limited detail on outpatient ECG monitoring after the initial hospitalization.

References:
[1] [1] Singh S, Zoble RG, Yellen L, et al. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. Circulation. 2000;102(19):2385-2390. doi:10.1161/01.cir.102.19.2385

Dofetilide in Patients with Congestive Heart Failure and Left Ventricular Dysfunction
Design	Randomized, double-blind, placebo-controlled study N=1518
Objective	To evaluate whether dofetilide affects survival or morbidity among patients with reduced left ventricular function and congestive heart failure
Study Groups	Dofetilide (n=762) Placebo (n=756)
Inclusion Criteria	Patients hospitalized with new or worsening congestive heart failure, NYHA class III or IV, wall-motion index ≤1.2, age ≥18, postmenopausal or using contraception, provided informed consent
Exclusion Criteria	Acute myocardial infarction within 7 days, heart rate <50 bpm, untreated sinoatrial block or AV block, history of drug-induced proarrhythmia, QTc >460 msec, diastolic BP >115 mm Hg, systolic BP <80 mm Hg, serum potassium <3.6 or >5.5 mmol/L, recent use of class I or III antiarrhythmics, creatinine clearance <20 ml/min, serious liver dysfunction, acute myocarditis, planned cardiac surgery or angioplasty, aortic stenosis, recent cardiac surgery, presence of an implantable cardioverter–defibrillator (ICD)
Methods	Patients from 34 Danish hospitals were randomized to dofetilide or placebo, stratified by center and degree of LV dysfunction. All patients were hospitalized and continuously monitored for the first 72 hours after treatment initiation to identify and treat early arrhythmic events. Initially, dosing differed by baseline atrial fibrillation status, but after protocol amendment, dofetilide dosing was selected by calculated creatinine clearance. Patients with CrCl 40 to <60 mL/min received 250 mcg twice daily; CrCl 20 to <40 mL/min received 250 mcg once daily. Dose reduction or discontinuation occurred for excessive QT/QTc prolongation, defined as >20% above baseline or >550 msec, or for adverse effects; any proarrhythmic event triggered discontinuation. Follow-up visits occurred at 1 month, 3 months, and every 3 months thereafter.
Duration	Median follow-up of 18 months
Outcome Measures	Primary: Death from any cause Secondary: Worsening congestive heart failure, conversion to and maintenance of sinus rhythm
Baseline Characteristics		Dofetilide (n= 762)	Placebo (n= 756)
	Median duration of heart failure, mo	12	12
	Mean age, years	70	70
	Male	72%	75%
	Current smoker	33%	35%
	Myocardial infarction	51%	52%
	Ischemic heart disease	67%	67%
	Diabetes	20%	19%
	Hypertension	15%	15%
	Creatinine clearance, ml/min	57 ± 23	57 ± 25
	Atrial fibrillation	25%	27%
	Wall-motion index, median	0.9	0.9
	Beta-blocker	9%	11%
	ACE inhibitor	72%	76%
	Calcium-channel blocker	20%	22%
	NYHA class I II III IV	2% 35% 56% 6%	2% 39% 51% 7%
	Abbreviations: ACE, angiotensin-converting enzyme.
Results		Dofetilide (n= 762)	Placebo (n= 756)	p-value
	Death from any cause	311 (41%)	317 (42%)	0.54
	Hospitalization for worsening heart failure	30%	38%	<0.001
	Hospitalizations for worsening CHF	352	422	<0.001
	Conversion to sinus rhythm at 1 month	22 of 190 (12%)	3 of 201 (1%)	<0.001
	Maintenance of sinus rhythm	Hazard ratio 0.35		P<0.001
Adverse Events	25 cases of torsade de pointes in the dofetilide group (3.3%) compared to none in the placebo group. Prolongation of the corrected QT interval was more frequent in the dofetilide group (2% vs. 0.4%).
Study Author Conclusions	In conclusion, dofetilide did not increase the risk of death among patients with congestive heart failure and reduced left ventricular function, was effective for the treatment of atrial fibrillation, and significantly reduced the risk of hospitalization for worsening congestive heart failure. The dose of dofetilide must be titrated carefully according to renal function, and treatment must be initiated together with a minimum of 72 hours of cardiac monitoring.
Critique	This large, randomized, placebo-controlled trial provides direct evidence supporting inpatient initiation of dofetilide with continuous monitoring, because most torsade de pointes events and peak QTc increases occurred early after initiation. However, the study population was limited to patients with severe LV dysfunction/heart failure, so its EKG-monitoring findings are most directly applicable to high-risk cardiac patients rather than all dofetilide candidates.

References:
[1] Torp-Pedersen C, Møller M, Bloch-Thomsen PE, et al; Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med. 1999;341(12):857-865. doi:10.1056/NEJM199909163411201.

Phase IV Trial Evaluating the Effectiveness and Safety of Dofetilide
Design	Retrospective analysis N= 107
Objective	To determine the effectiveness and safety of dofetilide in clinical practice as well as to ascertain whether clinicians are following established dosing guidelines
Study Groups	All patients (n= 107)
Inclusion Criteria	Patients ≥18 years of age who received dofetilide at VCU Medical Center between April 2000 and May 2002
Exclusion Criteria	Patients who received direct current cardioversion during the evaluation period
Methods	Retrospective analysis of patients who received dofetilide, evaluating guideline adherence and safety. Safety assessment included monitoring for excessive QTc interval prolongation and torsade de pointes. Effectiveness was assessed in patients receiving at least 36 hours of dofetilide for persistent atrial fibrillation/flutter (AFF), with appropriate dosing per guidelines, and without direct current cardioversion.
Duration	April 2000 to May 2002
Outcome Measures	Primary: Conversion of persistent AFF at 36 hours Secondary: Incidence of excessive QTc interval prolongation, compliance with established treatment guidelines
Baseline Characteristics		Study Group (n= 107)	EMERALD Trial (n= 129)	SAFIRE-D Trial (n= 77)
	Mean age, years (range)	62 (22 to 81)	65 (NA)	67 (33 to 87)
	Male	63 (58.9%)	86 (66.7%)	63 (81.2%)
	Primary indication Persistent AFF Paroxysmal AFF Ventricular arrhythmia/ICD	37 (34.6%) 63 (58.9%) 7 (6.5%)	129 (100%) 0 0	77 (100%) 0 0
	Structural heart disease	36 (33.6%)	63 (48.8%)	59 (76.6%)
	Hypertensive disease	50 (46.7%)	61 (47.3%)	46 (59.7%)
	Pacemaker/ICD	22 (20.6%)	NA	NA
	Estimated creatinine clearance >60 mL/min	87 (81.3%)	102 (79.1%)	49 (63.6%)
	Abbreviations: ICD, implanted cardiac defibrillator.
Results	In the overall safety cohort (n= 107), excessive QTc prolongation occurred in 19 patients (17.8%) after the first dofetilide dose and in 28 patients (26.2%) during subsequent dosing, while no cases of torsade de pointes were observed. In subgroup analyses, QTc prolongation after the first dose was numerically more frequent among patients aged ≥65 years versus <65 years (19.6% vs 16.4%), women versus men (20.5% vs 15.9%), and patients with versus without structural heart disease (27.6% vs 14.1%), although these differences were not statistically significant. During subsequent dosing, excessive QTc prolongation remained numerically more frequent in patients aged ≥65 years versus <65 years (32.6% vs 21.3%) and women versus men (29.5% vs 25.4%), with no significant between-group differences; however, patients with structural heart disease had a significantly higher incidence than those without structural heart disease (48.3% vs 17.9%; p< 0.01). In the effectiveness cohort (n= 25), conversion and maintenance of sinus rhythm at 36 hours occurred in 48% of patients, which was higher than the combined 36-hour conversion rate reported in the EMERALD and SAFIRE-D trials (27.2%; p= 0.05). Guideline adherence was imperfect: 15 patients (14.0%) received doses inconsistent with manufacturer recommendations, 5.6% of prescriptions were written by nonconfirmed prescribers, and 12.1% of patients had a potential drug–drug interaction.
Adverse Events	Excessive QTc interval prolongation occurred in 17.8% of patients after the first dose and 26.2% during subsequent doses. No patients developed torsade de pointes.
Study Author Conclusions	In clinical practice, the conversion of persistent AFF with dofetilide is at least comparable to premarketing studies, with a similar safety profile. Institutions should continue to emphasize adherence with established treatment guidelines.
Critique	This retrospective analysis is directly useful because it reports real-world adherence to dofetilide initiation guidance, including baseline ECG, telemetry, QTc reassessment 2–3 hours after the first dose, and discontinuation thresholds after subsequent doses. The main limitations are its single-center retrospective design, small effectiveness cohort, and short 3-day safety assessment window; however, the high rate of QTc prolongation, especially in structural heart disease, supports strict inpatient ECG/QTc monitoring during dofetilide initiation and close adherence to renal-dose and drug-interaction protocols.

References:
[1] [1] Guanzon AV, Crouch MA. Phase IV trial evaluating the effectiveness and safety of dofetilide. *Ann Pharmacother.* 2004;38(7-8):1142-1147. doi:10.1345/aph.1D465